COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Enalapril in Collagen Type 4 Nephropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01465126
Recruitment Status : Completed
First Posted : November 4, 2011
Last Update Posted : November 4, 2011
Information provided by (Responsible Party):
Maria Helena Vaisbich, University of Sao Paulo

Brief Summary:
Background: Collagen IV-related nephropathies can lead to End Stage Renal Disease. Experimental studies have shown renin angiotensin aldosterone system blockade can reduce proteinuria and preserve renal function. In humans there is no proven treatment. Methods: This is a retrospective study of patients with Collagen IV-related nephropathies and proteinuria treated with enalapril analyzing the evolution of proteinuria and renal function, as well as predictive variables of progression to end stage renal disease. Outcome was creatinine clearance < 60 ml/min/1.73m2.

Condition or disease
Collagen Type-4 Nephropathies

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 19 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Collagen Type 4-related Nephropathies: From Alport to Thin Membrane Nephropathy. A Series of Cases Treated With Angiotensin Converting Enzyme Inhibitor
Study Start Date : January 2011
Actual Primary Completion Date : October 2011
Actual Study Completion Date : October 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Primary Outcome Measures :
  1. proteinuria [ Time Frame: two years ]
    evaluate the proteinuria during two years of treatment with enalapril

Secondary Outcome Measures :
  1. evaluate the creatinine clearance during treatment with enalapril [ Time Frame: two years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with Collagen type 4 nephropathies and proteinuria followed in Pediatric Nephrology Unit of Instituto da Criança - HCFMUSP

Inclusion Criteria:

  • age under 18 years old
  • non-adherent to the exams and evaluations

Exclusion Criteria:

  • creatinine clearance < 60 ml/minute/1.73m2BS
Layout table for additonal information
Responsible Party: Maria Helena Vaisbich, Principal Investigator, University of Sao Paulo Identifier: NCT01465126    
Other Study ID Numbers: Registry Identifier
First Posted: November 4, 2011    Key Record Dates
Last Update Posted: November 4, 2011
Last Verified: November 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Urologic Diseases